Structured Review

Takeda dexlansoprazole mr
Mean <t>dexlansoprazole</t> plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Dexlansoprazole Mr, supplied by Takeda, used in various techniques. Bioz Stars score: 88/100, based on 40 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dexlansoprazole mr/product/Takeda
Average 88 stars, based on 40 article reviews
Price from $9.99 to $1999.99
dexlansoprazole mr - by Bioz Stars, 2022-10
88/100 stars

Images

1) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

2) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

3) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

4) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

5) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

6) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

7) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

8) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

9) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

10) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

11) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

12) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

13) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

14) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

15) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

16) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

17) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

18) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

19) Product Images from "Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease"

Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

Journal: Clinical and Experimental Gastroenterology

doi: 10.2147/CEG.S67672

Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
Figure Legend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

Techniques Used: Concentration Assay, Reflux, Modification

Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.
Figure Legend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

Techniques Used: Concentration Assay, Modification

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    Takeda dexlansoprazole mr
    Mean <t>dexlansoprazole</t> plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.
    Dexlansoprazole Mr, supplied by Takeda, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dexlansoprazole mr/product/Takeda
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    dexlansoprazole mr - by Bioz Stars, 2022-10
    88/100 stars
      Buy from Supplier

    Image Search Results


    Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

    Journal: Clinical and Experimental Gastroenterology

    Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

    doi: 10.2147/CEG.S67672

    Figure Lengend Snippet: Mean dexlansoprazole plasma concentration–time profiles (log-linear format) on day 7, following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules for 7 days, to pediatric patients 1 to 11 years of age with GERD. Abbreviations: GERD, gastroesophageal reflux disease; MR, modified release.

    Article Snippet: Exclusion criteria included evidence of current cardiovascular, central nervous system, pulmonary, or endocrine disease; hepatic, hematopoietic, renal, or metabolic dysfunction; serious allergy, asthma, or allergic skin rash; hypersensitivity to PPIs or components of dexlansoprazole MR; history of malignant disease or human immunodeficiency virus (HIV) infection; or positive test result for hepatitis B surface antigen or hepatitis C virus antibody.

    Techniques: Concentration Assay, Reflux, Modification

    Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

    Journal: Clinical and Experimental Gastroenterology

    Article Title: Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease

    doi: 10.2147/CEG.S67672

    Figure Lengend Snippet: Individual dexlansoprazole AUC t values versus ( A ) body weight and ( B ) dose on day 7 following once-daily administration of 15 mg, 30 mg, or 60 mg dexlansoprazole MR capsules to patients 1 to 11 years of age for 7 days. Note: Adult mean AUC values were 3,275 ng · hr/mL for the 30 mg dose and 6,529 ng · hr/mL for the 60 mg dose. 13 Abbreviations: AUC, area under the plasma concentration–time curve; AUC t , area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration; MR, modified release.

    Article Snippet: Exclusion criteria included evidence of current cardiovascular, central nervous system, pulmonary, or endocrine disease; hepatic, hematopoietic, renal, or metabolic dysfunction; serious allergy, asthma, or allergic skin rash; hypersensitivity to PPIs or components of dexlansoprazole MR; history of malignant disease or human immunodeficiency virus (HIV) infection; or positive test result for hepatitis B surface antigen or hepatitis C virus antibody.

    Techniques: Concentration Assay, Modification